We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Emily
Ashwin
emily.ashwin@ouh.nhs.uk
Dr
Ellie
Barnes
ellie.barnes@ndm.ox.ac.uk
Emily
Ashwin
emily.ashwin@ouh.nhs.uk
Diseases of liverMalignant neoplasms of digestive organs
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Liver cancer (HCC, hepatocellular cancer) is a major world-wide health problem and is one of the fastest rising and fourth commonest cause of death due to cancer world-wide. HCC usually arises in people with liver cirrhosis as a result of viral infections, alcohol excess and obesity, all of which cause the immune system to attack the liver.
Due to the increased risk of HCC, patients with liver cirrhosis usually have ultrasound scans and blood tests bi-annually, so that if a cancer develops this may be picked up in its early stages when it could be treated. However, these tests fail to detect liver cancer in 6 out of 10 people and the majority of people are first diagnosed when their cancer is too advanced to be cured. It remains unclear why and when people with liver cirrhosis develop cancer and little progress has been made to characterise the changes in the cirrhotic liver that leads to liver cancer.
The aim of this study is to recruit patients with small early liver cancers to 1) evaluate imaging and state-of-the art molecular biomarker tests to detect liver cancer at the earliest stages; 2) characterise the non-cancerous “background” liver to better understand the changes that may lead to cancer transformation; 3) to assess if biomarkers can be used to predict disease progression by clinical follow-up.
The SELINA study will recruit 200 HCC patients with and 50 without cirrhosis. Blood, urine and liver tissue samples will be collected for analysis. In a subgroup of patients, Magnetic Resonance liver Imaging will be performed. Patients will be follow-up up for a total of 14 years.
The study aims to identify novel blood biomarkers and to use new imaging techniques to detect HCC at the earliest time point so that treatments that may cure HCC can be given.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
Overall Study 1. Patients judged by the investigator to be unsuitable for inclusion in the study (e.g. where the investigator feels that the participant will not be able to comply with the study procedures) 2. HCC with liver cirrhosis at BCLC stage B/C 3. Patient who have had a previous liver transplant (note, it is permitted to enrol patients on the liver transplant waiting list if they fulfil all inclusion/exclusion criteria) 4. Participants of the PEARL study 5. Patients who have had a previous diagnosis of HCC followed by therapy, and now have a recurrence at the same site in the liver 6. Patients who have received therapy for HCC specific therapy 3 months prior to study visit 1 (including resection, ablation [microwave/radiofrequency]), transarterial chemoembolization [TACE], select internal radiation therapy [SIRT] or stereotactic body radiation therapy [SBRT] 3, chemotherapy, immune modulators and other experimental therapies). Exclusion Criteria for Imaging Subgroup 1. Any contra-indication to Magnetic Resonance Imaging (MRI) (e.g. claustrophobia, metal implants/fragments, implants, pregnancy, other conditions the scanner operator deems unsafe for MR scanning).
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Emily
Ashwin
emily.ashwin@ouh.nhs.uk
Emily
Ashwin
emily.ashwin@ouh.nhs.uk
Dr
Ellie
Barnes
ellie.barnes@ndm.ox.ac.uk
The study is sponsored by University of Oxford and funded by CANCER RESEARCH UK .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 49848
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
